Aza-BODIPY-Based Nanomedicines in Cancer Phototheranostics.
ACS Appl Mater Interfaces
; 12(24): 26914-26925, 2020 Jun 17.
Article
em En
| MEDLINE
| ID: mdl-32463220
Cancer phototheranostics, composed of optical diagnosis and phototherapy (including photodynamic therapy and photothermal therapy), is a promising strategy for precise tumor treatment. Due to the unique properties of near-infrared absorption/emission, high reactive oxygen species generation, and photothermal conversion efficiency, aza-boron-dipyrromethene (aza-BODIPY), as an emerging organic photosensitizer, has shown great potential for tumor phototheranostics. By encapsulating aza-BODIPY photosensitizers within functional amphiphilic polymers, we can afford hydrophilic nanomedicines that selectively target tumor sites via an enhanced permeability and retention effect, thereby efficiently improving diagnosis and therapeutic efficacy. Herein, in this spotlight article, we attempt to highlight our recent contributions in the development of aza-BODIPY-based nanomedicines, which comprises three main sections: (1) to elucidate the design strategy of aza-BODIPY photosensitizers and corresponding nanomedicines; (2) to overview their photophysical properties and biomedical applications in phototheranostics, including fluorescence imaging, photoacoustic imaging, photodynamic therapy, photothermal therapy, and synergistic therapy; and (3) to depict the challenges and future perspectives of aza-BODIPY nanomedicines. It is believed that this Spotlight on Applications article would illuminate the way of developing new aza-BODIPY nanomedicines as well as other organic photosensitizer-based nanomedicines for future clinical translation.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Fotoquimioterapia
/
Compostos de Boro
/
Nanomedicina
/
Neoplasias
Idioma:
En
Revista:
ACS Appl Mater Interfaces
Ano de publicação:
2020
Tipo de documento:
Article
País de afiliação:
China